Incysus Therapeutics Announces Presentations at 2018 ASH and HAPLO Annual Meetings
NEW YORK, Nov. 28, 2018 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the treatment of cancers, today announced that data related to the Company’s ongoing programs will be presented at the 60th American Society of Hematology Annual Meeting & Exposition (ASH) and at the 6th annual Haploidentical Transplant Symposium (HAPLO2018). Both meetings begin this week in San Diego, CA.
-- On Thursday, November 29, 2018, Lawrence S. Lamb, Ph.D., Professor of Medicine and Director of the Cell Therapy Laboratory at the University of Alabama at Birmingham (UAB) and Scientific Co-Founder of Incysus will join luminaries in the field of bone marrow transplantation and present at HAPLO2018. The presentation titled, “Evaluation of ex vivo Expanded and Activated γδ T Cells as Immune Support Against Relapse During Early Post-Transplant Recovery,” will occur during the Cell Therapy and Immune Reconstitution session that begins at 4:00 p.m. Pacific Time at the San Diego Marriott La Jolla Hotel.
2018 ASH Annual Meeting Presentations:
-- On Saturday, December 1, 2018, Dr. Lamb will moderate a panel as part of “Session 711. Cell Collection and Processing I”. The panel titled, “Hematology Disease Topics & Pathways: apheresis, bioengineering, Technology and Procedures, cell expansion, flow cytometry,” will begin at 9:30 a.m. Pacific Time in Grand Hall A of the Manchester Grand Hyatt San Diego. -- On Sunday, December 2, 2018, a poster (3410) entitled, “Impact of T-Cell Dose on Gvhd Risk After Allogeneic HLA-Matched PBSC Transplantation,” which supports the Company’s scientific approach and was authored by Ayman Saad, MD, of Ohio State University and a co-inventor of the Company’s initial technology, and co-authored by Dr. Lamb, will be presented as part of “Session 722. Clinical Allogeneic Transplantation” beginning at 6:00 p.m. Pacific Time in Hall GH of the San Diego Convention Center. The research for the poster was sponsored by the Center for International Blood and Marrow Transplant Research (CIBMTR).
“Our active participation in both the 2018 ASH and HAPLO2018 meetings reflects our dedication to the discovery, development and commercialization of a novel approach to treating serious and life-threatening cancers,” said William Ho, President and Chief Executive Officer of Incysus.
About CIBMTRThe CIBMTR® (Center for International Blood and Marrow Transplant Research®) is a research collaboration between the National Marrow Donor Program® (NMDP)/Be The Match® and the Medical College of Wisconsin (MCW). The CIBMTR collaborates with the global scientific community to advance hematopoietic cell transplantation (HCT) and cellular therapy worldwide to increase survival and enrich quality of life for patients. The CIBMTR facilitates critical observational and interventional research through scientific and statistical expertise, a large network of transplant centers, and a unique and extensive clinical outcomes database.
About 2018 ASH Annual MeetingWith more than 17,000 members from nearly 100 countries, the American Society of Hematology (ASH) is the world’s largest professional society serving both clinicians and scientists around the world who are working to conquer blood diseases. Expected to be the premier event in malignant and non-malignant hematology, the 60th ASH Annual Meeting & Exposition will be held in locations around San Diego, including the San Diego Convention Center, from December 1-4, 2018.
About HAPLO2018The Haploidentical Transplant Symposium, HAPLO 2018, is the sixth annual meeting of physicians and researchers involved in hematology and cellular therapy. The symposium focuses on the current challenges, best practices, and the latest discoveries in the field of haploidentical transplantation. The meeting will be held at the San Diego Marriott La Jolla Hotel on Thursday, November 29, 2018.
About Incysus Therapeutics, Inc.Incysus is focused on delivering a novel off-the-shelf cell therapy for the treatment of cancer. By using genetically modified gamma-delta (γδ) T cells, the Company’s technology addresses the challenges that immunotherapies face targeting cold, low mutation cancers. Incysus’ immuno-oncology programs include activated and gene-modified adoptive cellular therapies that protect cells from chemotherapy and allow novel combinations to disrupt the tumor microenvironment and more selectively target cancer cells. Since the Company’s inception in early 2016, Incysus has filed two Investigational New Drug applications (IND) and has initiated several cancer programs in early pre-clinical stages, including a checkpoint combination program. The Company’s first program is targeted to leukemia and lymphoma patients and the IND related to this program was accepted by the FDA in late 2017. The Company’s second program is targeted to treat patients with newly-diagnosed glioblastoma (GBM). In collaboration with the University of Alabama at Birmingham (UAB), Incysus has advanced its technology and expects to begin both Phase 1 trials in the first half of next year. For more information, visit www.incysus.com.
Contact:Incysus Therapeutics, Inc.(646) firstname.lastname@example.org